Abstract
Although numerous chemotherapeutic agents have been evaluated for patients with advanced prostate cancer, none have demonstrated improved survival benefits. Here, in order to determine whether the efficacy of chemotherapy can be enhanced by changing the regimen, we evaluated the effect of the varied timing and dosage of chemotherapy in combination with androgen withdrawal on time to androgen-independent (AI) progression in the human androgen-dependent LNCaP tumour model. We first demonstrated the synergistic effect of mitoxantrone on induction of apoptosis in LNCaP cells maintained in the steroid hormone-depleted charcoal-stripped media (CSM) compared to those in the standard media. In addition, this synergy was most remarkable during the simultaneous treatment of LNCaP cells with mitoxantrone and CSM compared to the pre- or post-use of mitoxantrone with CSM. LNCaP tumour growth in athymic nude mice and their increase in serum PSA levels were significantly inhibited by the simultaneous injection of mitoxantrone with castration, compared to the administration of mitoxantrone 2 weeks before or after castration. The TUNEL staining revealed that apoptotic cell death was extensively induced in LNCaP tumours treated with simultaneous castration and mitoxantrone compared to tumours treated with the other schedules. Furthermore, nude mice bearing LNCaP tumours were injected with a total of 0.5 mg mitoxantrone divided into 2, 5 and 10 days, with the most significant therapeutic effect and delayed AI progression observed in mice given injection of mitoxantrone for 2 days. These findings suggest that this might be the optimal way to perform cytotoxic chemotherapy and androgen withdrawal simultaneously in patients with advanced prostate cancer and to administer chemotherapeutic agents at high dosage within short intervals. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: prostate cancer, mitoxantrone, castration, androgen-independent progression, apoptosis
Full Text
The Full Text of this article is available as a PDF (183.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Denis L., Murphy G. P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer. 1993 Dec 15;72(12 Suppl):3888–3895. doi: 10.1002/1097-0142(19931215)72:12+<3888::aid-cncr2820721726>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
- Gleave M., Tolcher A., Miyake H., Nelson C., Brown B., Beraldi E., Goldie J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res. 1999 Oct;5(10):2891–2898. [PubMed] [Google Scholar]
- Hudes G. R., Nathan F. E., Khater C., Greenberg R., Gomella L., Stern C., McAleer C. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol. 1995 Oct;22(5 Suppl 12):41–45. [PubMed] [Google Scholar]
- Kantoff P. W., Halabi S., Conaway M., Picus J., Kirshner J., Hars V., Trump D., Winer E. P., Vogelzang N. J. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999 Aug;17(8):2506–2513. doi: 10.1200/JCO.1999.17.8.2506. [DOI] [PubMed] [Google Scholar]
- Miayake H., Tolcher A., Gleave M. E. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst. 2000 Jan 5;92(1):34–41. doi: 10.1093/jnci/92.1.34. [DOI] [PubMed] [Google Scholar]
- Miyake H., Hara I., Fujisawa M., Eto H., Okada H., Arakawa S., Kamidono S. Comparison of hormonal therapy and chemohormonal therapy in patients with newly diagnosed clinical stage D prostatic cancer. Int J Urol. 1996 Nov;3(6):472–477. doi: 10.1111/j.1442-2042.1996.tb00579.x. [DOI] [PubMed] [Google Scholar]
- Miyake H., Nelson C., Rennie P. S., Gleave M. E. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 2000 May 1;60(9):2547–2554. [PubMed] [Google Scholar]
- Miyake H., Nelson C., Rennie P. S., Gleave M. E. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 2000 Jan 1;60(1):170–176. [PubMed] [Google Scholar]
- Oh W. K., Kantoff P. W. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998 Oct;160(4):1220–1229. [PubMed] [Google Scholar]
- Tang D. G., Porter A. T. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate. 1997 Sep 1;32(4):284–293. doi: 10.1002/(sici)1097-0045(19970901)32:4<284::aid-pros9>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
- Tannock I. F., Osoba D., Stockler M. R., Ernst D. S., Neville A. J., Moore M. J., Armitage G. R., Wilson J. J., Venner P. M., Coppin C. M. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996 Jun;14(6):1756–1764. doi: 10.1200/JCO.1996.14.6.1756. [DOI] [PubMed] [Google Scholar]
- de Reijke T. M., Keuppens F. I., Whelan P., Kliment J., Robinson M. R., Rea L. A., Sylvester R. J. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. J Urol. 1999 Nov;162(5):1658–1665. doi: 10.1097/00005392-199911000-00023. [DOI] [PubMed] [Google Scholar]